Bacterial endotoxin (lipopolysaccharide [LPSJ) is known to interact with numerous components of blood, including erythrocytes, mononuclear cells, platelets, neutrophils, lipoproteins, and plasma proteins. The relative affinities of LPS for these elements, and the distribution of LPS between them, are unknown. Cross-linked stroma-free hemoglobin (SFH), a potential substitute for erythrocyte transfusion, produces in vivo toxicity in animals consistent with significant LPS contamination. Therefore, we studied the distribution of LPS in human and rabbit blood and examined whether the presence of SFH altered LPS distribution. In either the presence or absence of SFH, LPS was associated predominantly with high-density lipoproteins and apoproteins. There was lesser binding to low-and very-low-density lipoproteins. Examination of the apoprotein pool by column chromatography and density centrifugation demonstrated that LPS in this fraction was predominantly protein bound. Binding of LPS to SFH resulted in dissociation of a portion of the LPS into low-molecular-weight complexes. Cell-bound LPS was only 2 to 16% of the total and was unaffected by SFH. The distribution among blood cells demonstrated predominant binding to platelets in human blood but predominant binding to erythrocytes in rabbit blood. Cellular distribution was not significantly altered by SFH.
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Bacterial endotoxin (lipopolysaccharide [LPS] ) is the cell wall component of gram-negative bacteria responsible for initiation of fever, cardiovascular shock, and disseminated intravascular coagulation during septicemia. Endotoxin can enter the peripheral circulation at sites of wounds or the portal circulation by absorption and/or translocation from the gastrointestinal tract (30) . When endotoxin is administered parenterally to animals, much of the injected LPS is initially found in the cell-free fraction of plasma, with special affinity for high-density lipoproteins (HDL) (12) . Prominent binding to HDL has been shown in vitro (28, 46) . LPS association with protein also has clearly been demonstrated (41, 50) . Nevertheless, it has been known for several decades that LPS, when introduced into the blood of experimental animals, is rapidly cleared from the circulation (19, 23, 25) .
Interactions between LPS and circulating blood cells are of great interest since many of the deleterious effects of LPS during septicemia are the result of mediators released from inflammatory cells. LPS causes the release of a wide range of cell-derived substances, including cytokines (e.g., tumor necrosis factor [1, 7, 26, 43] , interleukin-1 [36, 48, 49] , and interleukin-6 [36, 48, 49] ), eicosanoids (22) , and procoagulants (e.g., tissue factor [34] ). However, animal studies have resulted in substantially discordant descriptions of the distribution of LPS among the various types of circulating blood cells. Injected LPS has been reported to associate preferentially with buffy coat cells (3) , platelets (19) , platelets, monocytes, and polymorphonuclear leukocytes (4) , and monocytes and polymorphonuclear leukocytes (23) or to be uniformly distributed between all cellular elements (24) . LPS interaction with erythrocytes has been clearly demonstrated in vitro (38) (39) (40) , although most in vivo animal studies of LPS distribution in blood have failed to demonstrate binding to * Corresponding author. erythrocytes. The quantitative distribution of LPS in human blood has not been reported.
There is experimental evidence that plasma proteins may influence the binding of LPS to other elements in blood, possibly by disaggregation of LPS (46) and/or by enhancement of the ability of LPS to bind to HDL (42) . Alteration of LPS by protein binding could potentially affect the clearance of LPS and/or the ability of LPS to stimulate the release of effector molecules from circulating blood cells (37, 47) . Cross-linked stroma-free hemoglobin (SFH) (defined in Addendum in Proof) is an oxygen-carrying protein being developed as an erythrocyte substitute for which endotoxin binding and a resultant synergistic toxicity are major concerns (51, 52) . When used as a resuscitation fluid after trauma, 100 g or more of SFH would potentially be infused into a patient. Endotoxin is likely to be present in the circulation during resuscitation after trauma because of skin and gut wounds and/or ischemia of the gastrointestinal tract. In addition, the infused SFH may have been contaminated by LPS during its production (10) . Therefore, the effect of SFH on the distribution of LPS in blood is an unknown but important variable during resuscitation therapy and of potentially great clinical relevance. The current study was undertaken to quantify the distribution of LPS in human blood and to determine if the distribution was altered by the presence of SFH.
MATERIALS AND METHODS
Reagents and labware. Percoll (adjusted to d = 1.07 or d = 1.09 g/ml) and Ficoll (adjusted to d = 1.07 g/ml) were purchased from Pharmacia LKB (Alameda, Calif.), and Mono-poly resolving medium was from Flow Laboratories (ICN Biomedicals, Inc., Costa Mesa, Calif. AH-4 swinging-bucket rotor, at 600 x g for 3 min, to obtain platelet-rich plasma and a cell pellet. The plasma was then centrifuged at 1,300 x g for 20 min to obtain platelets, and the platelet pellet was washed three times with 5 ml of PBS at 600 x g for 3 min. The cell pellet from the initial whole-blood centrifugation was resuspended in PBS to 8 Erythrocyte-containing fractions exhibited quenching of both 125I and 14C cpm. Therefore, 0.1-ml aliquots of erythrocyte fractions were diluted 10-fold in water (final volume, 1 ml), and 1.0 ml of Solvable (NEN Research Products) was added. These mixtures were incubated at 60°C for 1 h, and then 0.3 ml of 25% H202 was added. After 30 min of additional incubation at room temperature, samples were pale yellow in color and could be analyzed for radioactivity. Recovery of a spiked radioisotope in preliminary experiments demonstrated >98% detection of the previously added radioactivity.
All cell preparations were cytocentrifuged (Shandon Southern Instrument Co., Sewickley, Pa.), and 200 to 500 cell differentials were performed to determine purity.
Separation of lipoproteins from cell-free plasma. Separation of platelets from human or rabbit plasma, as described above, yielded cell-free plasma which contained less than 0.1% of starting platelets and undetectable numbers of leukocytes or erythrocytes (determined by Coulter counter analysis and examination of Wright-Giemsa-stained smears). The cell-free plasma was subjected to sequential ultracentrifugation (35) tube under these conditions, whereas protein-LPS complexes remained above the sucrose layer.
RESULTS
Distribution of endotoxin in human blood. The in vitro distribution of endotoxin in human blood was studied, in the presence or absence of SFH (defined in Addendum in Proof), by using radiolabeled E. coli 055:B5 LPS B or S. typhimurium LPS. In the absence of SFH, almost all of either of the radiolabeled endotoxins (96 to 98%) was associated with cell-free plasma ( Table 1) . Because of the predominance of plasma-associated counts, it was necessary to develop a procedure for isolating blood cells free of plasma to accurately determine cell-bound LPS. The procedure for cell isolation described in Materials and Methods was tested with whole blood to which 35S-labeled mouse plasma proteins (0.08 mCi; see Materials and Methods) had been added. Blood cells were isolated (see Materials and Methods) and 35S cpm were measured to determine the percentage of plasma contamination in each cell pool. Platelets were shown to be associated with only 0.015% of the total plasma cpm initially added; mononuclear cells were associated with 0.008%; polymorphonuclear leukocytes were associated with 0.008%; and erythrocytes were associated with 0.001%. This level of plasma contamination was equivalent to only 1 to 3% of the cpm detected in the samples of isolated blood cells, thus ensuring that the endotoxin detected with cells was actually cell bound and did not represent contamination by plasma endotoxin. This extremely low level of plasma contamination of blood cell samples was accomplished by the extensive washing steps described in Materials and Methods; consequently, recoveries of cells were diminished because of the multiple wash steps. Recoveries of cells, from a total of 47 individual experiments (23 human and 24 rabbit), were as follows: platelets, 49% + 21%; mononuclear cells, 14% + 10%; polymorphonuclear leukocytes, 62% + 30%; and erythrocytes, >99%.
In human blood, with both LPSs, 2 to 4% of the counts were cell associated (Table 1) . In all experiments (n = 23), the majority of the cell-associated endotoxin cpm was found in the platelet pool. Distribution among the remaining cell types was quite variable between experiments. Blood from five normal human volunteers was utilized, and no reproducible differences in endotoxin distribution among the types of blood cells were detected between individuals. In addition, LPS distributions were the same in heparinized and citratetreated blood samples from the same individual. Because of the predominance of platelet-associated cpm blood cell differentials were determined to ensure that cpm in the leukocyte and erythrocyte samples did not represent platelet contamination. Mononuclear cell preparations contained 76% + 15% lymphocytes and monocytes, 1% + 1% polymorphonuclear leukocytes, 17% + 13% erythrocytes, and 6% + 13% platelets (means + standard deviations [SD], 15 experiments). Polymorphonuclear leukocyte preparations contained 65% + 17% polymorphonuclear leukocytes, 34% + 19% erythrocytes, 2% + 7% platelets, and 0.1% ± 0.2% mononuclear cells (means ± SD, 15 experiments). The erythrocyte preparations contained greater than 99% erythrocytes, with less than 0.01% contamination with platelets. The low frequencies of platelets in the mononuclear leukocyte, polymorphonuclear leukocyte, and erythrocyte samples thus ensured that platelet-LPS contamination did not contribute to the presence of endotoxin in the preparations of the other types of circulating blood cells. Platelet-associated cpm contributed only 0.1% of the cpm in mononuclear cell preparations and 0.05% of the cpm in polymorphonuclear leukocyte preparations. Platelet preparations contained 99% ± 1% platelets (mean ± SD, 14 independent experiments).
The distribution of S. typhimurium endotoxin in human blood also was investigated in the presence of SFH. Almost all cpm (96%) were detected in cell-free plasma ( a Radiolabeled endotoxin was added to whole blood in the presence or absence of SFH. Cell-free plasma was then prepared and fractionated by sequential ultracentrifugation steps into VLDL (d < 1.006 g/ml), LDL (d = 1.006 to 1.063 g/ml), HDL (d = 1.063 to 1.21 g/ml), and apoproteins (d > 1.21 g/ml; plasma proteins remaining after sequential removal of lipoproteins). Recovery of added cpm from the cell-free plasma was 85% (mean value). Endotoxin distributions are expressed as means + SD.
b n, number of independent experiments. in general greater in rabbit blood than in human blood. Sixteen percent of the total cpm was cell associated in the absence of hemoglobin (n = 14), and 10% was cell associated in the presence of hemoglobin (n = 10). However, this difference was not significant. The distribution among cells demonstrated that 78% of the endotoxin cpm in the absence of SFH (n = 14) and 68% of the endotoxin cpm in the presence of SFH (n = 10) were associated with the erythrocytes, a distinct difference from the predominance of platelet-associated endotoxin among the cells in human blood. The few erythrocytes that contaminated mononuclear cell preparations (17% of cells) and polymorphonuclear leukocyte preparations (34% of cells) contributed only 0.01 and 0.03% of the cpm in these cell preparations, respectively. Cell-associated endotoxin distributions in the presence and absence of SFH were not significantly different. Distribution of endotoidn among the components of cell-free plasma. Cell-free plasma was fractionated by sequential ultracentrifugation steps, as described in Materials and Methods, into VLDL, LDL, HDL, and apoproteins (d > 1.21 g/ml). The distributions of 14C-labeled S. typhimurium endotoxin among these components in both human and rabbit plasma samples and in the presence and absence of SFH are shown in Table 2 . In both species, the relative magnitude of the distributions of endotoxin was HDL > apoproteins > LDL > VLDL.
Apoprotein fractions (d > 1.21 g/ml) from rabbit plasma samples containing "4C-labeled S. typhimurium endotoxin were then fractionated by G-150 gel permeation chromatography. In the absence of SFH, all radioactivity eluted in the void volume (molecular mass, >200 kDa; Fig. 1 ). This pattern was detected in each of five independent samples chromatographed. Considerable A280 also was present in the void volume, and numerous protein bands were detected in this material by polyacrylamide gel electrophoresis in sodium dodecyl sulfate (data not shown). In four apoprotein samples containing SFH, the majority of the cpm similarly was present in the void volume, although small amounts of radioactivity (5 to 24%) also were detected in the included volume (Fig. 2) . SFH, as measured by A570, was detected primarily in the included volume, although a small absorbance peak also was detected in the void volume. The retained peak of 14C-endotoxin coeluted with the peak of SFH (Fig. 2) . In contrast, 14C-endotoxin alone eluted exclusively in the void volume (four experiments, data not shown). Thus, the endotoxin, which eluted in the included volume derived from samples containing SFH, was partially disaggregated.
Since the majority of cpm in the fraction of plasma with a density greater than 1.21 g/ml (i.e., which contained apoproteins) eluted in the void volume of Sephadex G-150, as did endotoxin alone, it was unclear whether endotoxin in this plasma fraction was protein bound. To distinguish unbound from bound endotoxin, sedimentation through sucrose was performed. Preliminary experiments demonstrated that unbound endotoxin sedimented through 20% sucrose (Table 3) , under the conditions described in Materials and Methods, whereas plasma proteins or free SFH was predominantly less dense than the sucrose solution and, after centrifugation, remained in the aqueous layer above the sucrose cushion. Void volume fractions, from two samples to which SFH had not been added and two which contained SFH, were centrifuged over 20% sucrose. Endotoxin cpm in each of the four Sephadex G-150 void volume fractions remained predominantly in the layer above the sucrose, indicating that the endotoxin was comigrating with the proteins both in the presence and absence of SFH (Table 3) . Endotoxin cpm from the included volume peak of a sample containing SFH similarly demonstrated that the endotoxin was primarily comigrating with protein in the layer above the sucrose (presumably SFH; compare Fig. 1 and 2) .
To confirm the observation that endotoxin in the fraction of plasma with a density greater than 1.21 g/ml was protein bound, 11 additional apoprotein samples (5 without SFH and 6 with SFH) containing "'C-LPS were generated. These fractions were then subjected to sedimentation through 20% sucrose without prior chromatography. Each of these samples demonstrated that the majority of endotoxin cpm was present in the aqueous phase above the sucrose cushion (Table 3) . Most of the plasma proteins, as estimated byA280, also were present in this top zone. These observations were consistent with a major decrease in density of endotoxin in the presence of plasma proteins, most likely due to a disaggregation of high-molecular-mass endotoxin macromolecules (typically greater than 1,000 kDa in the absence of protein) secondary to protein binding.
Since endotoxin was detected in the included volume of Sephadex G-150 chromatography in the presence of SFH (Fig. 2) , it seemed likely that endotoxin had formed a specific complex with SFH. Therefore, we examined whether endo- toxin and SFH could form a stable complex in the absence of any other blood components. "4C-labeled S. typhimurium LPS (6.8 x 104 cpm) was incubated with 0.5 ml of SFH (1.2 g/dl) at room temperature for 15 min. The mixture was then layered above 20% sucrose and centrifuged as described in Materials and Methods. Ninety-eight percent of the endotoxin cpm was detected in the SFH layer above the sucrose, 1.9% of the cpm was in the top three-fourths of the sucrose layer, and only 0.1% of the cpm was at the bottom of the sucrose layer. In contrast, a control tube of endotoxin in PBS demonstrated 97% of the endotoxin in the bottom fraction.
DISCUSSION
The relative affinities of LPS for specific cellular, lipoprotein, and apoprotein components of whole blood have not been described previously. Therefore, we performed in vitro studies of the distribution of endotoxin in samples of whole blood by using two purified, commonly studied enteric LPSs. In both human and rabbit blood, endotoxin associated primarily with the noncellular components of blood. Binding to HDL was greatest, followed by binding to apoproteins. and VLDL were observed. In human blood, cell-associated endotoxin was detected primarily with platelets. However, the platelet-bound cpm constituted only 1 to 2% of the total endotoxin cpm distributed throughout the blood. In rabbit blood, the cell-associated endotoxin was primarily bound to erythrocytes; this constituted 10 to 16% of the total endotoxin cpm distributed throughout the blood. The demonstration of binding of LPS to platelets in humans, and to erythrocytes in rabbits, is potentially of relevance to the development of disseminated intravascular coagulation during endotoxemia. Several biological consequences of the interaction of LPS with mammalian platelets have been described previously, including the LPS-induced aggregation of human platelets (33) , activation and secretion of platelet factor 3 (20) , and secretion of 5-hydroxytryptamine (6) . The latter two processes were described in rabbits (human platelets were not studied). Therefore, it is interesting that the endotoxins tested in our study had affinity for human platelets but not for rabbit platelets. Human platelets are less responsive to endotoxin than are rabbit platelets (29) , but the pyrogenic response of humans to endotoxin exceeds that of rabbits (17) . It is possible that these differences reflect species-specific cell membrane characteristics. The membranes of human platelets and megakaryocytes previously have been shown to differ biochemically from murine platelets and megakaryocytes by the presence of Fc receptors (and their absence on murine platelets and megakaryocytes) (32) . In contrast, the murine cells demonstrate type 1 complement receptors, while the human cells do not (32) . Whereas LPS binding to human platelets is likely to result in significant physiological effects on hemostasis, the significance of LPS binding to rabbit erythrocytes is less clear. However, a glycoprotein receptor on erythrocyte membranes that binds LPS has been described, and its potential role in the etiology of immune hemolysis during sepsis has been discussed (40) .
Previous in vivo studies have demonstrated that much of administered LPS associates with HDL (12, 28, 46) . The binding of high-molecular-weight LPS particles to HDL involves the dissociation of LPS (45), a process involved in VOL. 61, 1993 on October 20, 2017 by guest http://iai.asm.org/ Downloaded from LPS detoxification, and has been shown to result in altered electrophoretic behavior of HDL (12) . The role of an apoprotein factor(s) in LPS binding to HDL has been demonstrated (27, 42) . LPS-binding protein appears to be one such apoprotein that is a mediator of LPS dissociation and binding to HDL (41) . We also have shown prominent binding of LPS to HDL, as well as demonstrable, although lesser, binding to the other classes of lipoproteins. However, the lipoprotein binding of exogenously administered, isolated LPS may not totally mimic the distribution of shed LPS, associated with bacterial outer member structures, as demonstrated previously for the LPS of S. typhimurium (28) and Neisseria meningitidis (2) . Shed LPS also may demonstrate variable lipoprotein binding depending on the presence or absence of bacterial membrane proteins (13) . Although numerically less impressive, the binding to VLDL in our study also may be biologically significant. It has been shown previously that binding of LPS to triglyceride-rich lipoproteins (VLDL and chylomicrons) diminishes the potency of LPS in activation of the coagulation system in Limulus lysate (8) . Furthermore, VLDL and chylomicrons protect mice from LPSinduced mortality (18) . Since hypertriglyceridemia is one of the earliest abnormalities observed in blood during sepsis, this interaction between LPS and the triglyceride-rich lipoproteins may serve as a defense against endotoxemia.
The presence of SFH at a concentration of 1.2 g/dl did not appreciably alter the distribution of endotoxin among the various blood cell types, lipoproteins, and the apoprotein pool in either human or rabbit blood. However, since we demonstrated that endotoxin was able to bind to SFH, it is possible that the distribution of endotoxin among specific plasma proteins of the apoprotein pool was significantly altered by the presence of hemoglobin. Furthermore, in contrast to the binding of LPS to another apoprotein, aggregated immunoglobulin G, after which the density of the complex was identical to that of LPS alone (16) , we have demonstrated that binding of LPS to SFH involves disaggregation of LPS (unpublished observations). Since the distribution of endotoxin among specific plasma proteins in the presence and absence of SFH is not known, further fractionation experiments will be required to determine if endotoxin binds to SFH preferentially. Several mammalian endotoxinbinding proteins in plasma have been documented previously, including a rabbit acute-phase LPS-binding protein (41) , lysozyme (31), complement (5, 14) , immunoglobulin (16) , and albumin (15) . We are now able to add SFH to this list of endotoxin-binding proteins.
The capacity of SFH to act as an endotoxin-binding protein may prove significant for the potential use of SFH as a blood substitute. Endotoxin contamination of SFH during its production and purification has been recognized (11; personal observations), and even low concentrations of endotoxin in preparations of SFH may prove clinically significant when liters of SFH solutions are infused into patients, especially those who are already hypotensive. It also is likely that endotoxemia will be present in many patients with trauma and shock who would be receiving this blood product. Gramnegative bacteremia associated with infection is another clinical situation in which endotoxin-hemoglobin binding may be a significant phenomenon. Endotoxin-hemoglobin complexes also may form as a result of the hemolysis that often occurs during the process of disseminated intravascular coagulation associated with gram-negative sepsis.
Importantly, our data indicate that the presence of SFH does not alter the association of endotoxin with mononuclear cells, an interaction which appears to play a critical pathophysiologic role in the production of the sepsis syndrome. However, further investigation will be required to determine if endotoxin-hemoglobin complexes differ from endotoxin alone in their ability to stimulate production or release of mononuclear cell factors involved in the response of the host to sepsis. Additional study also will be required to determine if endotoxin clearance from either the circulation or internal organs is altered by complex formation with hemoglobin.
